

Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/G4CD3DF766FEN.html>

Date: April 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: G4CD3DF766FEN

Abstracts

Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer and other diseases. The company's marketed antibodies include, ofatumumab (Kesimpta) for the treatment relapsing multiple sclerosis, daratumumab (Darzalex) are indicated for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 10,2021: Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

Feb 22,2021: Genmab announces appointment of Tahamtan Ahmadi to newly created position of chief medical officer head of experimental medicines

Jan 26,2021: Genmab announces 2020 net sales of DARZALEX (daratumumab)

Nov 19,2020: ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease

Nov 04,2020: Genmab announces data to be presented at 2020 ASH Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Genmab AS - Key Facts
Genmab AS - Key Employees
Genmab AS - Key Employee Biographies
Genmab AS - Major Products and Services
Genmab AS - History
Genmab AS - Company Statement
Genmab AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Genmab AS - Business Description
Product Category: License Revenue
Performance
Product Category: Milestone Revenue
Performance
Product Category: Reimbursement Revenue
Performance
Product Category: Royalties
Performance
Geographical Segment: Denmark
Performance
Geographical Segment: Japan
Performance
Geographical Segment: The Netherlands
Performance
Geographical Segment: The US
Performance
R&D Overview
Genmab AS - Corporate Strategy
Genmab AS - SWOT Analysis
SWOT Analysis - Overview
Genmab AS - Strengths

Genmab AS - Weaknesses
Genmab AS - Opportunities
Genmab AS - Threats
Genmab AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genmab AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 10, 2021: Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Feb 22, 2021: Genmab announces appointment of Tahamtan Ahmadi to newly created position of chief medical officer head of experimental medicines
Jan 26, 2021: Genmab announces 2020 net sales of DARZALEX (daratumumab)
Nov 19, 2020: ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease
Nov 04, 2020: Genmab announces data to be presented at 2020 ASH Annual Meeting
Nov 04, 2020: Genmab announces financial results for the first nine months of 2020
Oct 15, 2020: Genmab to host Capital Markets Day
Oct 14, 2020: Genmab announces data to be presented at SITC 35th anniversary annual meeting
Aug 12, 2020: Genmab announces financial results for the first half of 2020
Jun 11, 2020: AbbVie inks \$750m cancer therapeutics deal with Genmab

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Genmab AS, Key Facts
Genmab AS, Key Employees
Genmab AS, Key Employee Biographies
Genmab AS, Major Products and Services
Genmab AS, History
Genmab AS, Subsidiaries
Genmab AS, Key Competitors
Genmab AS, Ratios based on current share price
Genmab AS, Annual Ratios
Genmab AS, Annual Ratios (Cont...1)
Genmab AS, Interim Ratios
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Genmab AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Genmab AS, Performance Chart (2016 - 2020)

Genmab AS, Ratio Charts

Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Genmab AS, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/G4CD3DF766FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4CD3DF766FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970